The expanding role of long-acting beta-agonists.
J F
JF
Donohue
D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D003692:Delayed-Action Preparations; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D000068299:Salmeterol Xinafoate; D015996:Survival Rate
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations; D000068299:Salmeterol Xinafoate; D000420:Albuterol